Organigram (TSE:OGI) Director Purchases C$22,000.00 in Stock

Organigram Holdings Inc. (TSE:OGI) Director James Hideo Yamanaka acquired 20,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was acquired at an average cost of C$1.10 per share, for a total transaction of C$22,000.00. Following the completion of the purchase, the director owned 20,000 shares in the company, valued at C$22,000. The trade was a ∞ increase in their position.

Organigram Price Performance

TSE OGI traded up C$0.03 during trading hours on Monday, reaching C$1.59. The company’s stock had a trading volume of 131,673 shares, compared to its average volume of 219,245. The stock has a market cap of C$223.83 million, a PE ratio of -7.43, a PEG ratio of 0.42 and a beta of 1.72. Organigram Holdings Inc. has a fifty-two week low of C$1.44 and a fifty-two week high of C$3.09. The company’s 50-day moving average is C$1.86 and its two-hundred day moving average is C$2.07. The company has a debt-to-equity ratio of 2.20, a quick ratio of 2.62 and a current ratio of 2.82.

Analyst Upgrades and Downgrades

OGI has been the topic of a number of recent research reports. ATB Cormark Capital Markets lowered shares of Organigram from a “strong-buy” rating to a “moderate buy” rating and reduced their target price for the company from C$3.50 to C$3.25 in a report on Wednesday, February 11th. Canaccord Genuity Group set a C$3.00 target price on shares of Organigram and gave the company a “buy” rating in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Organigram presently has a consensus rating of “Buy” and a consensus target price of C$3.13.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.